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Summary
The oral proteasome inhibitor ixazomib is approved in the United States,
European Union and other countries, in combination with oral lenalido-
mide and dexamethasone (Rd), for the treatment of patients with multiple
myeloma who have received at least one prior therapy. Approval was based
on the global, randomised, double-blind, placebo-controlled Phase III
TOURMALINE-MM1 study of ixazomib-Rd (IRd) versus placebo-Rd in
patients with relapsed/refractory multiple myeloma. IRd resulted in a
significant improvement in progression-free survival versus placebo-Rd
(median: 206 vs. 147 months; hazard ratio 074). Common toxicities
observed more commonly with IRd versus placebo-Rd were thrombocy-
topenia, nausea, vomiting, diarrhoea, constipation, rash, peripheral neu-
ropathy, peripheral oedema and back pain; these were generally grade 1/2
in severity except for thrombocytopenia (19% vs. 9% grade 3/4), which
appeared manageable and reversible, with no differences between arms in
significant bleeding or dose discontinuations. No cumulative toxicities were
observed, indicating the potential feasibility of long-term IRd treatment.
Safety data from TOURMALINE-MM1 are reviewed and guidance for
managing clinically relevant adverse events associated with IRd is provided.
Most toxicities were manageable with supportive care and dose delays or
reductions as needed. Clinicians should be aware of and understand these
potential side effects to optimise and prolong patient benefit.
Keywords: multiple myeloma, ixazomib, toxicity, proteasome inhibitor,
dosing.
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Treatment options available for patients with newly diag-
nosed and relapsed/refractory multiple myeloma (RRMM)
have increased over the past decade, resulting in improved
outcomes (Kumar et al, 2014a; Moreau & Touzeau, 2015;
Cornell & Kassim, 2016). Combinations of proteasome inhi-
bitors (PIs) and immunomodulatory drugs are among the
most effective regimens, but historically, the parenteral route
of PI administration and their associated toxicities have lim-
ited duration of therapy (Rajkumar, 2012; Moreau & Tou-
zeau, 2015). Ixazomib is the first oral PI to enter the clinic
(Kumar et al, 2014b, 2015a; Richardson et al, 2014). Phase I/
II results for the combination of ixazomib, lenalidomide and
dexamethasone (IRd) demonstrated encouraging efficacy with
this all-oral PI/immunomodulatory drug-based regimen and
showed the feasibility of long-term therapy (Kumar et al,
2014c,d), providing support for the subsequent pivotal Phase
III study.
Ixazomib was approved, in combination with lenalidomide
and dexamethasone, by the United States Food and Drug
Administration in 2015, Health Canada in 2016, and the
European Commission in 2016, as well as in other countries
worldwide, for the treatment of patients with MM who have
received at least one prior therapy (http://www.ninlaro.com/
downloads/prescribing-information.pdf), based on outcomes
from the TOURMALINE-MM1 trial. TOURMALINE-MM1
was a global, randomised, double blind, placebo-controlled
Phase III clinical study of IRd versus placebo plus lenalido-
mide and dexamethasone (placebo-Rd) in adult patients with
RRMM (Moreau et al, 2016). Progression-free survival (PFS)
was significantly improved with IRd versus placebo-Rd
(median: 206 vs. 147 months; hazard ratio 074; P = 0012)
at a median follow-up of ~15 months; overall survival (OS)
data were not mature at a subsequent analysis with a median
follow-up of ~23 months (Moreau et al, 2016). Herein we
perform an in-depth analysis of the adverse events (AEs)
associated with IRd at the 23-month analysis, and review AE
management with a view to delivering optimal therapeutic
outcomes.
Methods
TOURMALINE-MM1 (NCT01564537) has been previously
reported (Moreau et al, 2016). Briefly, adult RRMM patients
who had received 1–3 prior therapies were eligible. Patients
were excluded if refractory to PI or lenalidomide, had failed
to recover (grade ≤1 toxicity) from effects of prior
chemotherapy (except alopecia), had peripheral neuropathy
(PN) of grade 1 with pain or grade ≥2 or evidence of uncon-
trolled cardiovascular conditions.
Patients were randomised 1:1 to receive oral ixazomib
4 mg (n = 360) or matching placebo (n = 362) on days 1,
8 and 15, plus oral lenalidomide 25 mg on days 1–21
(dose reduced for renal impairment per local prescribing
information) and oral dexamethasone 40 mg on days 1, 8,
15 and 22, in 28-day cycles. The primary endpoint was
PFS; key secondary endpoints were OS and OS in patients
with del(17).
Information regarding toxicity was graded using National
Cancer Institute Common Terminology Criteria for Adverse
Events (NCI-CTCAE) v4.0 (http://evs.nci.nih.gov/ftp1/
CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.
pdf). Attribution of toxicities to one or more drugs was at
the investigator’s discretion. Drug doses were omitted for sig-
nificant attributable toxicity and could be restarted with dose
reductions, once the toxicity resolved, per protocol. Ixazomib
(or placebo, in this double-blind study) dose was reduced to
3 mg, 23 mg and then discontinued for persistent toxicity.
Lenalidomide dose was reduced to 15 mg, 10 mg, 5 mg and
then discontinued if toxicities did not resolve or recurred.
Dexamethasone dose-reduction steps included 20 mg, 12 mg
and 4 mg, followed by discontinuation. Patients completed
quality-of-life (QoL) questionnaires at pre-specified intervals.
Blood samples (3 ml) were collected on day 1 of cycle 2
for measurement of ixazomib trough plasma concentrations,
using a validated liquid chromatography/tandem mass spec-
trometry assay (Gupta et al, 2016a). Graphical analyses were
used to evaluate exposure-safety relationships. Observed pro-
portions of AEs were defined as the number of events/num-
ber of observations and were plotted for each exposure
(Ctrough) quartile. Three haematological AEs (anaemia, neu-
tropenia, thrombocytopenia) and six non-haematological AEs
(diarrhoea, fatigue, nausea, PN, rash, vomiting) were anal-
ysed. The dependent variable was the presence or absence of
an AE during the study, specifically grade ≥3 events for
haematological AEs and grade ≥2 events for non-haematolo-
gical AEs.
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Results
A total of 722 patients were enrolled (Figure S1); baseline
demographic and disease characteristics were well balanced
between groups (Moreau et al, 2016). With a median follow-
up of ~23 months (data cut-off 12 July, 2015), the median
number of treatment cycles was 170 (range: 1–34 cycles) for
IRd and 150 (range: 1–34 cycles) for placebo-Rd. Dose
intensity was high (median relative dose intensity, defined as
percentage of total dose taken divided by total planned dose
over treated cycles, for lenalidomide and dexamethasone was
938% and 922% in the IRd group, and 966% and 949%
in the placebo-Rd group; median relative dose intensity for
ixazomib was 974%, and for placebo was 988%) suggesting
that addition of ixazomib did not compromise the back-
ground Rd regimen (Moreau et al, 2016).
The most common AEs are shown in Table I (Moreau et al,
2016). Differences between groups were mostly due to higher
frequencies of low-grade events with IRd. The frequency of
grade ≥3 AEs was higher with IRd versus placebo-Rd (74% vs.
69%) primarily due to the higher incidence of thrombocytope-
nia; the frequency of grade 4 AEs (18% vs. 15%) was similar
between groups. Frequencies of serious AEs (47% vs. 49%),
on-study deaths (4% vs. 6%), dose discontinuation of any
agent due to an AE (25% vs. 20%) and discontinuation of the
treatment regimen due to an AE (17% vs. 14%) were similar
with IRd versus placebo-Rd (Moreau et al, 2016).
Haematological events
Thrombocytopenia. Thrombocytopenia is an overlapping
toxicity of ixazomib and lenalidomide (Benboubker et al,
2014; http://www.revlimid.com/wp-content/uploads/2013/11/
PI.pdf.; Kumar et al, 2014b,c; Lonial et al, 2005; Reece et al,
2012; Richardson et al, 2014). It was reported nearly twice as
frequently with IRd versus placebo-Rd (31% vs. 16%; includ-
ing 12% vs. 5% grade 3, 7% vs. 4% grade 4), but platelet
counts of ≤10 9 109/l and ≤5 9 109/l were infrequently
reported (IRd: 2% and <1%; placebo-Rd: 1% and <1%).
Despite the higher incidence of grade 3/4 thrombocytopenia
with IRd versus placebo-Rd, rates of platelet transfusions
(8% vs. 6%) and haemorrhage events of any grade (20% vs.
19%) were similar. First occurrence of thrombocytopenia
was highest during the first 3 months of treatment in the
IRd (68/112; 61%) and placebo-Rd (29/57; 51%) groups and
the incidence generally declined over time. Platelet counts
showed a cyclical pattern, dropping after each ixazomib dose,
with nadirs around day 14–21, and returning to baseline
levels prior to initiation of the subsequent cycle, with no
long-term cumulative effect (Fig 1). Thrombocytopenia lead-
ing to discontinuation of any drug occurred in five patients
(1%) in the IRd group (associated with disease progression
in two patients) and seven patients (2%) in the placebo-Rd
group.
Neutropenia. Neutropenia is a relatively common side effect
with many drugs used for MM treatment and increases the
risk of infectious complications, especially if severe and pro-
longed (Palumbo et al, 2012; Dimopoulos et al, 2015a;
Valkovic et al, 2015). The incidence of neutropenia was simi-
lar with IRd and placebo-Rd (33% vs. 31%; including 18%
vs. 18% grade 3, 5% vs. 6% grade 4), and was transient and
cyclical in nature. The median time to documented recovery
was 80 and 120 days with IRd and placebo-Rd, respectively.
Table I. AEs of clinical importance occurring in at least 20% of patients in either arm.
AE category, n (%)
Placebo-Rd (n = 359) IRd (n = 361)
AE Gr ≥3 SAE D/C AE Gr ≥3 SAE D/C
Haematological events*
Thrombocytopenia† 57 (16) 32 (9) 6 (2) 7 (2) 112 (31) 69 (19) 7 (2) 5 (1)
Neutropenia 111 (31) 85 (24) 2 (<1) 5 (1) 118 (33) 81 (22) 2 (<1) 3 (<1)
Non-haematological events*
Nausea 79 (22) 0 0 0 104 (29) 6 (2) 2 (<1) 0
Vomiting 42 (12) 2 (<1) 0 0 84 (23) 4 (1) 2 (<1) 0
Diarrhoea 139 (39) 9 (3) 2 (<1) 3 (<1) 164 (45) 23 (6) 9 (2) 6 (2)
Constipation 94 (26) 1 (<1) 1 (<1) 1 (<1) 126 (35) 1 (<1) 1 (<1) 0
Rash† 82 (23) 6 (2) 1 (<1) 1 (<1) 131 (36) 18 (5) 1 (<1) 3 (<1)
PN† 78 (22) 6 (2) 0 2 (<1) 97 (27) 9 (2) 0 9 (2)
Peripheral oedema‡ 73 (20) 4 (1) 1 (<1) 0 101 (28) 8 (2) 1 (<1) 0
Back pain 62 (17) 9 (3) 7 (2) 1 (<1) 87 (24) 3 (<1) 2 (<1) 0
AE, adverse event; D/C, discontinued; Gr, grade; IRd, ixazomib, lenalidomide and dexamethasone; Placebo-Rd, placebo plus lenalidomide and
dexamethasone; PN, peripheral neuropathy; SAE, serious adverse event.
*Grade 4 thrombocytopenia reported in 13 (4%) and 26 (7%) patients in the placebo-Rd and IRd groups, respectively; grade 4 neutropenia
reported in 22 (6%) and 17 (5%) patients, respectively. No grade 4 events reported for the non-haematological AEs listed here.
†Pooled preferred terms (broad pooling of standardized Medical Dictionary for Regulatory Activities query [SMQ] preferred terms).
‡An association between oedema and cardiac failure was similar between the two regimens (IRd: 1%; placebo-Rd: <1%).
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Neutropenia was reported most frequently within the first
three cycles, with no cumulative effect seen. Lenalidomide
was dose-reduced most frequently and similarly in the two
regimens (IRd: 8%; placebo-Rd: 7%); ixazomib or placebo
was reduced less frequently (4% in each regimen). The inci-
dence of patients with grade ≥3 neutropenia and AEs within
the ‘infections and infestations’ system organ class (SOC)
was also similar (IRd: 2%; placebo-Rd: 3%). Febrile neu-
tropenia was similarly infrequent with both regimens (<1%
and 2%, respectively). Colony-stimulating factors were used
by 21% and 20% of patients in the IRd and placebo-Rd
groups.
Non-haematological events
Nausea/vomiting. Nausea and vomiting are reported with
both lenalidomide and ixazomib (http://www.revlimid.com/
wp-content/uploads/2013/11/PI.pdf; http://www.ninlaro.
com/downloads/prescribing-information.pdf), but are more
common with ixazomib, as seen with the single-agent trials
(Kumar et al, 2014b, 2015a). Rates of nausea and vomiting
were higher with IRd than placebo-Rd (nausea: 29% vs.
22%; vomiting: 23% vs. 12%) (Moreau et al, 2016). Differ-
ences were primarily due to higher frequencies of low-grade
events with IRd (Table II). Individual agents were dose-
reduced for nausea in ≤2% and ≤1% of patients in the IRd
and placebo-Rd groups, respectively. There were no discon-
tinuations due to nausea or vomiting, and no apparent dif-
ferences between the IRd and placebo-Rd groups in
incidences of potential complications, such as dehydration
(2% vs. 1%) and weight loss (AE: 7% vs. 6%; mean change
in actual weight over time: 24 kg vs. 27 kg). In both
groups, the incidence of first occurrence of nausea was high-
est during the first 3 months of treatment, particularly in the
first cycle. Time to onset with IRd was primarily the day of
or after (12–48 h) ixazomib dosing. Nausea in the placebo-
Rd group was also reported each week.
Use of anti-emetics was at the physician’s discretion. Use
of prophylactic anti-emetics starting prior to the first dose of
study drugs was similar in both groups (IRd: 5%; placebo-
Rd: 2%), while 11% versus 5% reported starting these agents
for prophylactic use only after the first dose of study
IRd
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Fig 1. Median platelet and absolute neutrophil counts. (A) Median platelet count over cycles. (B) Median absolute neutrophil count over cycles.
C, cycle; D, day; IRd, ixazomib, lenalidomide, and dexamethasone; Placebo-Rd, placebo plus lenalidomide and dexamethasone.
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treatment. The most commonly prescribed anti-emetics were
ondansetron and metoclopramide.
Diarrhoea and constipation. Diarrhoea has been reported
with both lenalidomide and ixazomib, alone or in combina-
tion with dexamethasone (http://www.revlimid.com/wp-conte
nt/uploads/2013/11/PI.pdf; Kumar et al, 2014b, 2015a,b;
Lonial et al, 2015; http://www.ninlaro.com/downloads/
prescribing-information.pdf; Moreau et al, 2016; Pawlyn
et al, 2014). The increased frequency of diarrhoea with IRd
versus placebo-Rd (45% vs. 39%) was primarily due to a
higher frequency of low-grade events (Table II). The inci-
dence of diarrhoea was consistent with the lenalidomide pre-
scribing information (reported frequency of 40–46%) (http://
www.revlimid.com/wp-content/uploads/2013/11/PI.pdf). No
apparent differences were noted between the IRd and pla-
cebo-Rd groups in the incidence of potential complications
of diarrhoea, such as hypokalaemia (13% vs. 10%), dehydra-
tion, weight loss (per nausea/vomiting section), hypona-
traemia (2% vs. 2%) and hypomagnesaemia (4% vs. 5%).
The incidence of the first occurrence of diarrhoea was
highest during the first 3 months of treatment in both
groups and generally declined over time. With IRd, onset
was primarily on the day of or after ixazomib dosing, while
it was reported at a consistent rate each week in the placebo-
Rd group. Antidiarrhoeal medications were used to manage
diarrhoea at the physician’s discretion; loperamide was the
most commonly prescribed medication (IRd: 19%; placebo-
Rd: 15%). Discontinuation of individual drugs occurred in
≤2% and <1% of patients in the IRd and placebo-Rd groups,
respectively. Across both regimens, lenalidomide was the
agent most frequently dose-reduced for diarrhoea, followed
by dexamethasone and ixazomib/placebo. The incidence of
constipation was 35% with IRd and 26% with placebo-Rd,
which was all grade 1–2 (Table I); narcotic pain medications
for myeloma-related bone pain as a confounding factor can-
not be excluded. Use of laxatives was similar in the IRd and
placebo-Rd groups (38% vs. 35%).
Rash. The incidence of rash was 36% vs. 23% with IRd
versus placebo-Rd (Table I) (Moreau et al, 2016). The rash
observed with IRd typically ranged from limited ery-
thaematous, macular and/or papular lesions that could be
pruritic over a few areas of the body, to a more gener-
alised eruption predominantly on the trunk or extremities,
and as such is described best using the high-level term of
‘rashes, eruptions and exanthems’, which includes the pre-
ferred terms of rash maculo-papular, rash macular, rash
and rash generalized. The incidence of such rashes (pooled
terms) was 20% and 13% with IRd and placebo-Rd,
respectively, with the difference primarily due to a higher
frequency of low-grade events; grade 3 events were
reported in 5% and 2%, respectively.
The incidence of first occurrence of rash was highest dur-
ing the first 3 months of treatment and generally declined
over time in both groups. The median time to documented
recovery was 12 days in both groups. The rash events were
frequently self-limiting, with 21% and 12% of patients in the
IRd and placebo-Rd groups, respectively, reporting events
that resolved without intervention. Management approaches
included antihistamines (primarily cetirizine) or topical glu-
cocorticoids. Dose modification was also used, often with
lenalidomide being dose-modified first (IRd: dose reduced in
7%, held in 9%; placebo-Rd: dose reduced in 3%, held in
2%), and then ixazomib (IRd: dose reduced in 4%; held
in 3%) and dexamethasone (IRd: dose reduced in 2%, held
in 1%; placebo-Rd: dose reduced in <1%, held in <1%) sub-
sequently as needed. Rash leading to discontinuation of at
least one agent occurred in three patients (<1%) in the IRd
group (of lenalidomide in all three patients, and of ixazomib
and dexamethasone in two patients) and one patient (<1%)
in the placebo-Rd group (of lenalidomide).
Peripheral neuropathy. PN is a common finding in patients
with RRMM, either related to the underlying disease process
or due to prior treatment, usually thalidomide or bortezomib
(Richardson et al, 2012). At study entry, 26% of patients
(IRd: 23%; placebo-Rd: 30%) had either a medical history of
PN or reported PN at baseline. Additionally, more than 50%
of patients in both groups reported at least a little tingling in
their hands or feet on the European Organization for
Research and Treatment of Cancer Multiple Myeloma Mod-
ule (EORTC QLQ-MY20) questionnaire at baseline even if
the physician did not document a medical history of PN.
Overall incidence of PN (including peripheral sensory neu-
ropathy, neuropathy peripheral, and peripheral motor neu-
ropathy) was 27% and 22% in the IRd and placebo-Rd
Table II. Gastrointestinal toxicities with IRd and placebo-Rd.
Placebo-Rd
(n = 359)
IRd
(n = 361)
Nausea
Grade 1 (%) 15 22
Grade 2 (%) 7 5
Grade 3 (%)* 0 2
Time to documented recovery (days) 7 12
Vomiting
Grade 1 (%) 8 17
Grade 2 (%) 3 6
Grade 3 (%)* <1 1
Time to documented recovery (days) 1 1
Diarrhoea
Grade 1 (%) 22 24
Grade 2 (%) 14 15
Grade 3 (%)* 3 6
Time to documented recovery (days) 5 4
IRd, ixazomib, lenalidomide, and dexamethasone; Placebo-Rd,
placebo plus lenalidomide and dexamethasone.
*No grade 4 or 5 events were reported.
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groups, respectively. This was mainly sensory neuropathy
(IRd: 19%; placebo-Rd: 14%), with <1% in both arms expe-
riencing peripheral motor neuropathy. Most PN was grade 1/
2 (IRd: 24%; placebo-Rd: 20%), with only 2% in each group
reporting grade 3 PN (there was no grade 4 PN).
Among 175 patients who reported PN, 14% and 17% in
the IRd and placebo-Rd groups, respectively, had worsening
of PN during treatment. The overall incidence of PN with
pain was 3% and 2% in the IRd and placebo-Rd groups,
respectively. Most events were grade 1 or grade 2 in both the
IRd (five and seven patients, respectively) and placebo-Rd
(one and six patients, respectively) groups; one patient in
each group experienced grade 3 PN with pain. Of the 21
patients who experienced PN with pain, seven (IRd: three;
placebo-Rd: four) had PN at baseline.
In both groups, most PN occurred during the first
3 months of treatment and the incidence generally declined
over time, suggesting a lack of cumulative toxicity. Among
patients who reported new onset or worsening of PN, the
median time to onset was similar between the IRd and pla-
cebo-Rd groups (128 days and 125 days). Among patients
who reported PN, resolution was recorded in 36% in each
group. Median time to documented recovery was 535 days
and 485 days in the IRd and placebo-Rd groups,
respectively.
Infrequent clinically important AEs
Venous thromboembolism. The risk of venous thromboem-
bolism (VTE) is increased in patients with cancer (~7%
incidence), with higher rates (8–16%) reported in patients
with RRMM treated with Rd (Palumbo et al, 2008; Chen
et al, 2013). Thromboprophylaxis was required per proto-
col as all patients were receiving lenalidomide; 98% of
patients reported use of aspirin or an anticoagulant (IRd:
97%; placebo-Rd: 98%). A review of venous thrombosis in
aggregate identified a thromboembolism event in 29
patients (8%) in the IRd group and 38 patients (11%) in
the placebo-Rd group. Arterial thromboembolic events
were reported infrequently (2% in each group), consistent
with rates of VTE events previously reported for patients
with RRMM treated with Rd (Palumbo et al, 2008). Over-
all, the addition of ixazomib to Rd did not increase the
VTE risk.
Herpes zoster virus. Herpes zoster virus (HZV) was reported
in 5% and 2% of patients treated with IRd and placebo-Rd,
respectively. Among patients who started HZV prophylaxis at
study entry (n = 431), <1% and 1% in the IRd and placebo-
Rd groups, respectively, reported HZV infection. This is in
contrast to those that did not start HZV prophylaxis
(n = 291; frequency of 8% and 3% in the IRd and placebo-
Rd groups, respectively). Given this information, HZV pro-
phylaxis should be considered for patients receiving
ixazomib.
Other AEs of interest
Cardiac function. Cardiac toxicity has been a focus of several
trials including PIs (San Miguel et al, 2013; Atrash et al,
2015; Mikhael, 2016). There were no safety concerns with
respect to cardiac toxicity for ixazomib. There were similar
frequencies of cardiac arrhythmia in the two groups (IRd:
16%; placebo-Rd: 15%). The incidences of heart failure (4%
for both) and myocardial infarction (1% and 2%, respec-
tively) were similar in the IRd and placebo-Rd groups. In
particular, no increase in cardiac events was demonstrated in
patients with pre-existing heart disease or cardiac risk factors
(defined as myocardial infarction, cardiac ischaemia, angina,
arrhythmia, congestive heart failure, valvular diseases, hyper-
tension, diabetes, hyperlipidaemia or obesity).
Renal and hepatic dysfunction. There were no safety con-
cerns regarding renal impairment; the incidence of the stan-
dardized Medical Dictionary for Regulatory Activities
(MedDRA) query (SMQ) for acute renal failure, which cap-
tures a broad range of related individual preferred terms, was
low and similar between the IRd and placebo-Rd groups (9%
vs. 11%). Similarly, there were no safety concerns with
respect to AEs associated with liver impairment (7% vs. 6%).
Based on pharmacokinetic and safety data, a reduced ixa-
zomib starting dose of 30 mg is recommended in patients
with severe renal impairment or end-stage renal disease, and
in patients with moderate-to-severe hepatic impairment
(Gupta et al, 2016a,b).
Ocular events. The incidence of AEs in the eye disorders
SOC was 32% and 23% in the IRd and placebo-Rd groups,
respectively. The higher frequency with IRd was accounted
for by differences in rates of low-grade events within individ-
ual preferred terms associated with conjunctival irritation,
such as blurred vision (7% vs. 4%), conjunctivitis (7% vs.
2%) and dry eye (5% vs. 2%). Considering the similar fre-
quencies between regimens, no safety concerns were noted
with regards to these ocular events.
Secondary primary malignancies. No difference in the occur-
rence of secondary primary malignancies was observed with
IRd versus placebo-Rd (5% vs. 4%, respectively); 31 patients
(14 in the IRd group and 11 in the placebo-Rd group) were
diagnosed with a new malignancy. Haematological new
primary malignancies included myelodysplastic syndrome
(1 patient in each group) and T-cell acute lymphoblastic leu-
kaemia (1 patient in the placebo-Rd group). Solid tumours
of heterogeneous types occurred in 8 and 2 patients in the
IRd and placebo-Rd groups, respectively. Non-haematologi-
cal skin malignancies occurred in 8 and 10 patients in the
IRd and placebo-Rd groups, respectively. A clinically relevant
medical history (prior history of adenomas and/or smoking)
or prior treatment history (melphalan with or without autol-
ogous stem cell transplantation) was noted in 7 of 17 and 3
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of 14 patients diagnosed with a new malignancy in the IRd
and placebo-Rd groups, respectively.
Quality of life. QoL, as measured by the EORTC QLQ-C30
and MY-20 questionnaires, was similar in the two groups
and was maintained throughout treatment (Leleu et al,
2016).
Exposure-safety analysis
The graphical exposure-safety analysis used data from 328
patients with safety and ixazomib trough concentration data
at cycle 2, day 1. The analyses included selected haematologi-
cal and non-haematological AEs. There appeared to be a
relationship between ixazomib concentration and higher inci-
dences of selected AEs, suggesting the appropriateness of
dose modifications for these AEs (Figure S2).
Discussion
The TOURMALINE-MM1 results clearly demonstrate the
overall safety profile of adding ixazomib to Rd. The toxicity
profile of the triplet is favourable and appears comparable to
that of the Rd doublet; this represents a beneficial efficacy-
toxicity relationship given the PFS improvements seen. The
toxicities that increased in incidence with addition of ixa-
zomib appear to include thrombocytopenia, nausea, vomit-
ing, diarrhoea, constipation, rash, PN, peripheral oedema
and back pain. The haematological toxicity is predictable
from prior experience with PIs, with transient, cyclical
thrombocytopenia appearing to be a class effect (Lonial et al,
2005; Nooka, 2013). The increased gastrointestinal toxicity
also reflects experience with bortezomib (Richardson et al,
2005; San Miguel et al, 2008), while the PN rate was lower
than reported with bortezomib (Moreau et al, 2011). Rash
was reported with single-agent ixazomib (Kumar et al,
2014b; Richardson et al, 2014); however, the feasibility of
reliable comparison versus other PIs is limited due to differ-
ences in AE reporting, e.g., based on individual preferred
terms or pooled terms/MedDRA queries. Notably, toxicities
seen with the addition of ixazomib were mostly grade 1/2,
except for thrombocytopenia, for which grade 3/4 AEs were
also seen more frequently.
The increased incidence of grade 3/4 thrombocytopenia
did not have any clinical consequence in terms of significant
bleeding or dose discontinuations. No cumulative effect on
platelet counts was seen and thrombocytopenia appeared to
be manageable with no lasting consequences. If dose modifi-
cation is considered warranted (Table III), alternating dose
reduction of lenalidomide and ixazomib is recommended,
given that thrombocytopenia is reported with both agents.
Platelet counts should be monitored at least monthly during
ixazomib treatment, and more frequent monitoring (weekly)
should be considered during the first three cycles until steady
dosing is achieved. Neutropenia was similar in both arms;
management should follow dose-modification guidelines
(http://www.revlimid.com/wp-content/uploads/2013/11/PI.pdf;
http://www.ninlaro.com/downloads/prescribing-information.
pdf) with use of colony-stimulating factors per standard
medical guidelines (Smith et al, 2015) (Table III).
Management of gastrointestinal toxicity is particularly
important given the oral nature of IRd. Considering the eme-
togenic potential of ixazomib, adequate anti-emetic therapy
based on patients’ needs and prophylactic anti-emetics,
where appropriate, should be considered (Hesketh et al,
2016). Use of serotonin receptor antagonists prior to
Table III. Dose modifications guidelines for ixazomib in combination with lenalidomide and dexamethasone: haematological toxicities.
Haematological toxicities Recommended actions*
Thrombocytopenia
Platelet count <30 9 109/l • Withhold ixazomib and lenalidomide until platelet count is ≥30 9 109/l
• Following recovery, resume lenalidomide at the next lower dose according to its prescribing information and
resume ixazomib at its most recent dose
• If platelet count falls <30 9 109/l again, withhold ixazomib and lenalidomide until platelet count is
≥30 9 109/l
• Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at its most recent dose†
Neutropenia
ANC <05 9 109/l • Withhold ixazomib and lenalidomide until ANC is ≥05 9 109/l. Consider adding G-CSF as per clinical
guidelines
• Following recovery, resume lenalidomide at the next lower dose according to its prescribing information and
resume ixazomib at its most recent dose
• If ANC falls to <05 9 109/l again, withhold ixazomib and lenalidomide until ANC is ≥05 9 109/l
• Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at its most recent dose†
ANC, absolute neutrophil count; G-CSF, granulocyte colony-stimulating factor.
*Per NINLARO prescribing information (http://www.ninlaro.com/downloads/prescribing-information.pdf).
†For additional occurrences, alternate dose modification of lenalidomide and ixazomib.
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ixazomib dosing effectively ameliorates nausea and should be
considered in patients who develop nausea. Delayed-onset
nausea has been uncommon. Although diarrhoea was
reported more frequently with IRd versus placebo-Rd, man-
agement should be similar to that in patients receiving Rd
(Reece et al, 2012). Prophylactic anti-diarrhoeal medication
is not recommended, although anti-diarrhoeal medications
(primarily loperamide) and dose modification of lenalido-
mide or ixazomib should be used as needed. Diarrhoea was
generally manageable and did not appear to have clinical
implications. The incidence of constipation was higher with
IRd and was manageable with routine measures including
diet and laxative adjustments (Tariman, 2007).
Rash was seen with IRd, reflecting the overlapping nature
of this toxicity that has been seen with ixazomib alone
(Kumar et al, 2014b) and with lenalidomide (Reece et al,
2012; Tinsley et al, 2015). Most lenalidomide-related rash is
of mild-to-moderate severity and presents as patchy, raised
macular skin lesions, sometimes with localised urticaria and/
or pruritus (Reece et al, 2012; Tinsley et al, 2015). Although
serious dermatological reactions, including Stevens-Johnson
syndrome (SJS) and toxic epidermal necrolysis (TEN), have
been reported with lenalidomide (http://www.revlimid.com/
wp-content/uploads/2013/11/PI.pdf) and SJS has been
reported with IRd previously (Richardson et al, 2013), there
were no occurrences of SJS or TEN. In the Phase I/II trial of
IRd, skin rash was manageable with standard medical treat-
ment and dose withholding/reductions as needed (Kumar
et al, 2014c). Alternating dose modification of the potentially
causative agents, lenalidomide and ixazomib, was utilised in
TOURMALINE-MM1 and in line with the lenalidomide pre-
scribing information (http://www.revlimid.com/wp-content/
uploads/2013/11/PI.pdf), and appears to be an acceptable
strategy (Table IV). As with lenalidomide-induced rash,
symptomatic management with oral/topical antihistamines
and/or topical corticosteroids should be employed as needed
(Tariman, 2007; Reece et al, 2012; Tinsley et al, 2015). As
other medications commonly used in the management of
MM patients may cause rash, consideration of this alternative
aetiology is important and discontinuation of such agents
(e.g., antimicrobial agents, allopurinol) should be considered
(Stern, 2012).
Patients receiving IRd should be monitored continuously
for symptoms of PN. In one analysis, 36–83% of patients
had either a medical history of PN or PN at baseline in
RRMM clinical trials (Dimopoulos et al, 2015b); contempo-
rary studies have reported PN rates of 17–22% for Rd (Chen
et al, 2009; Stewart et al, 2015; Moreau et al, 2016). Patients
Table IV. Dose modifications guidelines for IRd: non-haematological toxicities.
Non-haematological toxicities and severity* Recommended actions†
Rash
Grade 2 or 3 • Withhold lenalidomide until rash recovers to grade ≤1
• Following recovery, resume lenalidomide at the next lower dose according to its prescribing
information
• If grade 2 or 3 rash occurs again, withhold ixazomib and lenalidomide until rash recovers to
grade ≤1
• Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at its
most recent dose‡
Grade 4 • Discontinue treatment regimen
Peripheral neuropathy
Grade 1 with pain or grade 2 • Withhold ixazomib until peripheral neuropathy recovers to grade ≤1 without pain or patient’s
baseline
• Following recovery, resume ixazomib at its most recent dose
Grade 2 with pain or grade 3 • Withhold ixazomib. Toxicities should, at the physician’s discretion, generally recover to
patient’s baseline condition or grade ≤1 prior to resuming ixazomib
• Following recovery, resume ixazomib at the next lower dose
Grade 4 • Discontinue treatment regimen
Other toxicities
Grade 3/4 • Withhold ixazomib. Toxicities should, at the physician’s discretion, generally recover to
patient’s baseline condition or grade ≤1 prior to resuming ixazomib
• If attributable to ixazomib, resume ixazomib at the next lower dose following recovery
IRd, ixazomib, lenalidomide, and dexamethasone; PN, peripheral neuropathy.
*Grading based on National Cancer Institute Common Terminology Criteria v4.03.
†Per NINLARO prescribing information (http://www.ninlaro.com/downloads/prescribing-information.pdf).
‡For additional occurrences, alternate dose modification of lenalidomide and ixazomib.
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experiencing new or worsening PN require dose modification
(Table IV). Additionally, management of PN symptoms, e.g.,
with the anti-seizure drugs gabapentin and pregabalin, tri-
cyclic antidepressants and opioid analgesics, should be con-
sidered. Drug-induced PN may be irreversible; hence, careful
attention to symptoms, prevention and appropriate dose
modification/discontinuation remain the most effective
strategies (Delforge et al, 2010).
The majority of peripheral oedema was independent of car-
diac function, low-grade, and probably related to fluid reten-
tion induced by dexamethasone and vascular permeability
effects described for proteasome inhibition (Tamura et al,
2010). Notably, the frequency of peripheral oedema for both
lenalidomide (263%) and dexamethasone (211%) described
in the lenalidomide prescribing information is consistent with
frequencies in TOURMALINE-MM1 (http://www.revlimid.
com/wp-content/uploads/2013/11/PI.pdf). Patients should be
evaluated for underlying causes and provided with supportive
care as necessary, including adjustment of dexamethasone or
ixazomib dosing per prescribing information for grade 3/4
symptoms (http://www.accessdata.fda.gov/drugsatfda_docs/
label/2004/11664slr062_decadron_lbl.pdf; http://www.ninlaro.
com/downloads/prescribing-information.pdf).
The relationships between ixazomib concentration and
AEs suggest the appropriateness of dose modifications for
these AEs (e.g., rash, PN, diarrhoea, nausea, vomiting,
thrombocytopenia, anaemia). The results of these exposure-
safety analyses, together with the overall safety profile,
support management of AEs via dose modification and
supportive care.
Therapy-related AEs, plus the multiple difficulties in
managing complex MM-related symptoms, have a negative
impact on patients’ QoL (Osborne et al, 2012, 2014; Baz
et al, 2015). In the context of the feasibility of long-term
therapy, tolerability and QoL are important factors for
RRMM patients. Over a median follow-up of 23 months,
QoL was maintained with IRd compared to placebo-Rd
(Moreau et al, 2016), and there was limited additional toxic-
ity to add to the patient burden, as well as no additional
physician office visits with IRd versus Rd. This is notable in
the context of other PI-Rd or monoclonal antibody-Rd regi-
mens, for which frequent physician visits for subcutaneous
or lengthy intravenous administration of the PI or mono-
clonal antibody are required.
In conclusion, the IRd safety profile was generally manage-
able and added limited toxicity to the Rd background regi-
men. The observed toxicities were familiar for lenalidomide
and reported in the literature (http://www.revlimid.com/
wp-content/uploads/2013/11/PI.pdf; Dimopoulos et al, 2007;
Reece et al, 2012; Weber et al, 2007) and generally consistent
with those in studies of single-agent ixazomib (Kumar et al,
2014b; Richardson et al, 2014) and IRd (Kumar et al, 2014c;
Gupta et al, 2015). Toxicities were manageable with routine
supportive care and dose delays or reductions (Moreau et al,
2016). The most common haematological toxicity heightened
by ixazomib was thrombocytopenia. Non-haematological
AEs, such as nausea/vomiting, diarrhoea, rash and PN were
generally grade 1/2. No cumulative toxicities were observed,
and specifically no evidence of cumulative haematological
toxicity or PN, indicating the potential feasibility of long-
term IRd treatment. Ongoing patient/caregiver education is
necessary and reinforces the importance of symptom aware-
ness in order to maximise patient self-reporting so that toxi-
cities can be appropriately managed with prompt standard
medical interventions. Based on the efficacy and favourable
toxicity profile observed in this study, IRd represents an
appropriate regimen for patients with RRMM.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Fig S1. CONSORT diagram.
Fig S2. Ixazomib Ctrough versus individual AEs of clinical
importance (grade ≥2 for non-haematological and grade ≥3
for haematological AEs). Ixazomib exposure range in each
quartile is denoted by the horizontal black line. Black dots
(vertical lines) represent the observed proportion of patients
(95% CI) in each quartile. n/N is the number of patients
with events/total number of patients in each quartile. The
exposure metric for ixazomib in the exposure-safety analyses
was trough concentration data at cycle 2, day 1 (n = 328
evaluable patients). The analyses were conducted on selected
haematological and non-haematological AEs. Three haemato-
logical AEs (defined as grade ≥3 anaemia, neutropenia and
thrombocytopenia) and six non-haematological AEs (defined
as grade ≥2 diarrhoea, fatigue, nausea, peripheral neuropathy,
rash and vomiting) were analysed. There appeared to be a
visual relationship between ixazomib concentration and
higher incidences of the AEs examined (rash, diarrhoea, nau-
sea, vomiting and thrombocytopenia); these were primarily
low-grade, manageable AEs without major clinical complica-
tions (see Discussion of AEs in main text). Decreasing expo-
sure from an ixazomib dose of 4 mg to 3 mg corresponded
to a decrease in the risk of developing the examined AEs.
Therefore, the results of these analyses support management
of AEs via dose modifications and supportive care in main-
taining patients on ixazomib for as long as clinically
indicated.
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